Sir, In the Guidelines for prophylaxis and treatment of methicillinresistant Staphylococcus aureus (MRSA) infections in the UK, 1 the Joint Working Party states for empirical treatment that 'The prevalence level at which flucloxacillin or other penicillinasestable penicillins, in a patient group, becomes no longer the drug of choice is debatable, but 10% resistance has been used as a guide for avoiding the use of empirical gentamicin in Gram-negative infection and we would recommend the same threshold is used when contemplating treatment of staphylococcal infections with isoxazolylpenicillins or cephalosporins. This threshold may be adjusted depending on the apparent severity of infection. ' This threshold (of 10%) ignores the evidence that b-lactam drugs are more effective than glycopeptides for infections caused by methicillin-susceptible S. aureus (MSSA) in the eradication of infection, prevention of recurrence and prevention of death. [2] [3][4][5][6][7] Moreover, it was impossible to show an advantage of glycopeptide appropriate empirical treatment over inappropriate treatment. 8 The 10% threshold means that in order to offer appropriate treatment (vancomycin) to 10 patients with severe infections caused by MRSA, 90 people with severe infections caused by MSSA will be given less effective treatment (vancomycin and not cloxacillin).
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To try and take this factor into account, we have looked at 429 patients with S. aureus bacteraemia included in the Beilinson Bacteremia Database. 9, 10 The fatality rate in patients given inappropriate empirical antibiotic treatment was 38% (69 of 183), versus 24% (57 of 246) in patients given appropriate treatment, P = 0.007. The multivariable-adjusted odds ratio was 1.8 [95% confidence interval (CI) 1.2-2.7]. 9 In patients with MSSA bacteraemia, the fatality rate was 28% (47 of 166) in patients treated with vancomycin versus 8% (4 of 48) in patients given cloxacillin, P = 0.004, univariate odds ratio of 4.3 (95% CI 1.5-12.8). The multivariable-adjusted odds ratio was larger than the univariate ones.
If indeed the advantage of cloxacillin over vancomycin as empirical treatment is at least as large as that of appropriate versus inappropriate treatment, the threshold of the baseline susceptibility to methicillin for preferring vancomycin over cloxacillin in a patient suspected of harbouring a severe infection with S. aureus should be 50% rather than 10%.
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We have no conflicts of interest to declare. 1 The central tenet of their hypothesis is the inhibition of purine nucleoside phosphorylase (PNP) by tenofovir or its metabolites such that an accumulation of deoxyribonucleotides, particularly dGTP, leads to a specific T-lymphocytopenia. This situation is akin to congenital immunodeficiency disorders caused by deficiency in PNP activity. We reported a similar hypothesis earlier and are encouraged to see that the issue has not been forgotten. 2 In our report, we also linked the pharmacology of PNP inhibition to the poor antiviral response to triple nucleoside reverse transcriptase inhibitor (NRTI) therapies that included tenofovir and other purine analogue NRTIs. We reasoned that poor antiviral potency would be a natural consequence of raised dGTP and dATP levels with which purine analogue NRTIs compete for HIV reverse transcriptase-catalysed incorporation. Subsequently, several articles have also demonstrated that tenofovir plus didanosine are not optimally potent when combined with non-NRTIs. 1 Unfortunately, the mechanism(s) for the poor responses and the paradoxical CD4 declines have not been determined. Studies have not detected intracellular pharmacokinetic interactions between tenofovir and the other NRTI components in patients. 1, 3 Furthermore, in vitro data are available for the effects of tenofovir and purine analogue combinations on viral replication and intracellular endogenous nucleotide pools. These studies were not discussed by Barreiro and Soriano. IL-2 and phytohaemagglutinin (PHA)-stimulated PBMCs or CEM-CCRF and MT-4 cells were cultured over 24-48 h with various concentrations of tenofovir alone or in combination with other NRTIs (abacavir, didanosine, lamivudine and combinations thereof). No anti-HIV antagonism was noted for various combinations of tenofovir and these other NRTIs. Measurements of intracellular 2 0 -deoxynucleotides and ribonucleotides appeared unchanged in the presence of tenofovir with and without the other NRTIs. One of these studies used ribavirin, hydroxyurea and methotrexate as positive controls and found these molecules to significantly change intracellular endogenous nucleotide pools, as expected. 4, 5 Whether these in vitro findings put the PNP inhibition hypothesis to rest is debatable. In vitro cellular pharmacology findings do not always predict what happens in the human body. As one illustration, stavudine and zidovudine were found to be additive against HIV replication with in vitro studies similar to those described above, but studies in patients found the combination to be antagonistic against HIV. 6 It is likely that the cellular pharmacology of tenofovir in combination with these other NRTIs in patients is at the heart of these undesirable responses whether or not PNP inhibition plays a role. Other pharmacological factors that are important to consider include differences in NRTI phosphorylation among different cell types. For example, the active intracellular phosphates for tenofovir, abacavir, lamivudine and didanosine, which were all present in some combination(s) for the undesirable clinical responses described above, are at the highest level relative to their endogenous counterparts in resting cells. 7, 8 Perhaps there is a disproportionate level of these pharmacologically active NRTI-triphosphates in resting versus activated cells. This potential compartmentalization of high or low intracellular NRTI-triphosphate concentrations could explain toxicity and suboptimal potency in various tissues and cells depending on their activation state. 7, 9 Furthermore, in terms of the suboptimal potency of didanosine plus tenofovir, the combination of therapeutic doses of two adenosine analogues may be less potent than therapeutic doses of analogues of two different bases (such as thymidine and cytidine). This is because the receptor theory of pharmacology asserts that maximum effects could have been reached with one adenosine analogue leaving little additional effect from the second adenosine analogue. Finally, another hypothesis for the triple NRTI failures is a low genetic barrier to resistance whereby the individual components select for similar mutations creating a synergic selection of specific mutations such as M184V or K65R. 1 In summary, it is important to understand the pharmacological mechanism(s) for these undesirable patient responses so that rational strategies can be devised to manage these problems clinically and to avoid similar problems in the future. These needs also underscore the importance of translational research to bridge bench-top findings to the clinical setting.
